newsVerastem licenses Duvelisib from Infinity Pharmaceuticals for $28 million3 November 2016 | By Niamh Louise Marriott, Digital Content ProducerVerastem licensed exclusive worldwide rights to develop and commercialise Infinity's oncology product candidate duvelisib...
newsPhase 1 study of Verastem’s FAK inhibitor, VS-6063, starts6 January 2016 | By Victoria WhiteThe Phase 1 study, initiated by Washington University, will evaluate VS-6063 in combination with pembrolizumab and gemcitabine in patients with pancreatic cancer...
newsVerastem reduces its workforce by 50%9 October 2015 | By Victoria WhiteVerastem’s announcement comes just weeks after the company had to abandon enrolment in a Phase 2 study of its lead cancer drug VS-6063...
newsVerastem stops enrolment in trial of VS-6063 in mesothelioma28 September 2015 | By Victoria WhiteWhile VS-6063 had a generally well tolerated safety profile, there was not a sufficient level of efficacy to warrant continuation of the study...
